These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors. Li X; Shen J; Tan L; Zhang Z; Gao D; Luo J; Cheng H; Zhou X; Ma J; Ding K; Lu X Bioorg Med Chem Lett; 2016 Jun; 26(12):2760-2763. PubMed ID: 27155899 [TBL] [Abstract][Full Text] [Related]
9. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors. Gould AE; Adams R; Adhikari S; Aertgeerts K; Afroze R; Blackburn C; Calderwood EF; Chau R; Chouitar J; Duffey MO; England DB; Farrer C; Forsyth N; Garcia K; Gaulin J; Greenspan PD; Guo R; Harrison SJ; Huang SC; Iartchouk N; Janowick D; Kim MS; Kulkarni B; Langston SP; Liu JX; Ma LT; Menon S; Mizutani H; Paske E; Renou CC; Rezaei M; Rowland RS; Sintchak MD; Smith MD; Stroud SG; Tregay M; Tian Y; Veiby OP; Vos TJ; Vyskocil S; Williams J; Xu T; Yang JJ; Yano J; Zeng H; Zhang DM; Zhang Q; Galvin KM J Med Chem; 2011 Mar; 54(6):1836-46. PubMed ID: 21341678 [TBL] [Abstract][Full Text] [Related]
10. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities. El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549 [TBL] [Abstract][Full Text] [Related]
12. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors. Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors. Yang W; Chen Y; Zhou X; Gu Y; Qian W; Zhang F; Han W; Lu T; Tang W Eur J Med Chem; 2015 Jan; 89():581-96. PubMed ID: 25462267 [TBL] [Abstract][Full Text] [Related]
14. Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-Raf Sun S; He Z; Huang M; Wang N; He Z; Kong X; Yao J Bioorg Med Chem; 2018 May; 26(9):2381-2391. PubMed ID: 29631788 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors. Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193 [TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors. Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752 [TBL] [Abstract][Full Text] [Related]
17. Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline. Smith AL; DeMorin FF; Paras NA; Huang Q; Petkus JK; Doherty EM; Nixey T; Kim JL; Whittington DA; Epstein LF; Lee MR; Rose MJ; Babij C; Fernando M; Hess K; Le Q; Beltran P; Carnahan J J Med Chem; 2009 Oct; 52(20):6189-92. PubMed ID: 19764794 [TBL] [Abstract][Full Text] [Related]
18. Identification of type II inhibitors targeting BRAF using privileged pharmacophores. Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives. Abdel-Maksoud MS; Kim MR; El-Gamal MI; Gamal El-Din MM; Tae J; Choi HS; Lee KT; Yoo KH; Oh CH Eur J Med Chem; 2015 May; 95():453-63. PubMed ID: 25841200 [TBL] [Abstract][Full Text] [Related]
20. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect. Pulici M; Traquandi G; Marchionni C; Modugno M; Lupi R; Amboldi N; Casale E; Colombo N; Corti L; Fasolini M; Gasparri F; Pastori W; Scolaro A; Donati D; Felder E; Galvani A; Isacchi A; Pesenti E; Ciomei M ChemMedChem; 2015 Feb; 10(2):276-95. PubMed ID: 25430902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]